These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 1981162

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
    Quik M, Police S, He L, Di Monte DA, Langston JW.
    Neuroscience; 2000; 98(2):263-73. PubMed ID: 10854757
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
    Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P.
    Eur J Neurosci; 2005 Feb; 21(4):841-54. PubMed ID: 15787691
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
    Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):103-8. PubMed ID: 15790534
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.
    Neurobiol Dis; 2012 Mar 24; 45(3):1051-67. PubMed ID: 22198503
    [Abstract] [Full Text] [Related]

  • 36. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
    Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD.
    Neuropharmacology; 1989 Nov 24; 28(11):1211-6. PubMed ID: 2512516
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
    Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep 24; 360(3):256-61. PubMed ID: 10543426
    [Abstract] [Full Text] [Related]

  • 40. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
    Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, Oriaku ET, Lamango NS, Soliman KF, Charlton CG.
    Pharmacol Biochem Behav; 2006 Mar 24; 83(3):349-59. PubMed ID: 16580056
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.